Kinases are enzymes whose job is to attach a phosphate group, borrowed from an energy-carrying molecule called ATP, onto another molecule. That target might be a protein, a sugar, a fat, or even another small molecule. The attachment of a phosphate group, called phosphorylation, acts like a molecular switch: it changes the shape, activity, or location of the target. Cells use this switch for nearly everything they do, from growing and dividing to responding to hormones and processing nutrients.
How Phosphorylation Works
ATP is the universal energy currency inside cells, and it carries three phosphate groups linked in a chain. When a kinase gets hold of ATP and a target molecule, it catalyzes the transfer of ATP’s outermost phosphate onto that target. The result is a target molecule with a new phosphate tag and a leftover molecule called ADP. This reaction needs the help of metal ions, usually magnesium, which hold the phosphate groups in the right orientation so the transfer can happen efficiently.
The protein kinase family shares a remarkably consistent physical structure. The enzyme folds into two lobes: a smaller one at the top and a larger one at the bottom. ATP nestles into a deep groove between them, held in place by a loop that contains a signature sequence of amino acids rich in glycine. A separate stretch called the activation loop provides a landing pad for the target molecule. When conditions are right, the kinase brings the phosphate group and the target close enough together for the transfer to occur in a rapid, coordinated step.
The Scale of the Kinase World
If you hear the word “kinase” in a biology or medicine context, it almost always refers to a protein kinase, an enzyme that phosphorylates other proteins. Humans carry roughly 540 genes encoding protein kinases, and a mapping project that built expression libraries for most of them managed to tag and locate about 460 of those inside living cells.
But protein kinases are only part of the story. Other kinases phosphorylate entirely different kinds of molecules. Hexokinase, for example, attaches a phosphate to glucose as the very first step of breaking sugar down for energy. Phosphofructokinase handles a later step in that same sugar-breakdown pathway and has long been considered one of the key pace-setters of the whole process.
Lipid kinases add phosphate groups to fats embedded in cell membranes. One well-studied family, called PI3K, phosphorylates a membrane lipid to produce signaling molecules that help the cell grow and survive. Recent work tracking where PI3K does its job found that both the production and the breakdown of its lipid products are confined to the outer membrane of the cell, with downstream signals being carried inward by proteins rather than by the lipid messengers themselves.
Then there are nucleotide kinases, which shuttle phosphate groups between the small energy-carrying molecules cells depend on. The point is that “kinase” is a functional label for any enzyme that performs a phosphate transfer, not a single family tree. What unites them all is the basic chemistry: take a phosphate from a donor, stick it on a recipient, and change what the recipient does.
Protein Kinases as Cellular Switches
Protein kinases are sometimes called the master regulators of cell biology, and the label is not much of an exaggeration. They control cell growth, movement, gene expression, metabolism, and death. The way they accomplish this is by acting in chains, or cascades, where one kinase phosphorylates and activates the next, amplifying a signal as it goes.
One of the best-known cascades is the MAPK pathway. It starts when a signal at the cell surface activates a kinase called Raf, which phosphorylates a kinase called MEK, which in turn phosphorylates a kinase called ERK. ERK then enters the nucleus and switches on genes involved in cell growth and survival. This chain of three kinases, each handing off to the next, is a classic example of how a faint signal at the surface can be amplified into a strong response deep inside the cell.
Another critical group is the cyclin-dependent kinases, or CDKs. These enzymes govern whether and when a cell divides. A CDK on its own is inactive; it only fires when it binds to a partner protein called a cyclin. Different cyclins appear and disappear at specific moments during the cell cycle, effectively setting a timer. When the right cyclin is present, its CDK partner phosphorylates the proteins needed to push the cell to the next stage of division. When the cyclin is destroyed, the kinase goes quiet again.
The On-Off Balance With Phosphatases
Phosphorylation would be useless as a switch if it could only be flipped in one direction. The counterparts to kinases are enzymes called phosphatases, which remove phosphate groups. Together, kinases and phosphatases create a dynamic push-and-pull that lets cells respond quickly to changing conditions and then reset. A growth signal might activate a cascade of kinases in seconds; once the signal fades, phosphatases strip the phosphates back off and silence the pathway. The balance between these two enzyme families is fundamental to how cells regulate growth, metabolism, and their responses to the environment.
Where a Kinase Sits in the Cell Matters
It is not enough for a kinase to be active; it also has to be in the right place. Researchers increasingly recognize that the physical location of a kinase inside the cell shapes what it can do. A kinase tethered near the nucleus encounters a different set of targets than the same kinase anchored at the outer membrane. Cells exploit this by using scaffolding proteins that physically tether kinases to specific compartments, bringing them close to the right targets and the right off-switches at the same time.
A well-studied example involves protein kinase A, or PKA, which responds to a second messenger called cyclic AMP. On its own, PKA would float around the cell somewhat aimlessly. Instead, a family of anchoring proteins called AKAPs pins PKA to particular locations, such as the membrane surrounding the nucleus, the inner surface of the cell membrane, or the scaffolding of the cell’s skeleton. AKAPs often also recruit phosphatases and other enzymes, assembling little signaling stations where the full activation-and-shutdown cycle can play out in a tightly controlled pocket of the cell.
When Kinases Go Wrong
Because kinases sit at the controls of so many cellular decisions, a kinase that gets stuck in the “on” position or starts firing when it shouldn’t can cause serious disease. Cancer is the most prominent example. Mutations that make a kinase permanently active can push cells to divide without stopping, ignore signals to self-destruct, and resist the normal checks on growth.
One of the clearest illustrations involves a chromosomal rearrangement found in certain leukemias. Parts of two genes, BCR and ABL, get fused together by a chromosomal swap, producing a hybrid protein called BCR-ABL. The ABL protein is normally a tightly regulated tyrosine kinase. But when BCR sequences are bolted onto it, the kinase loses its off-switch and phosphorylates targets continuously, driving the uncontrolled growth of white blood cells. This fusion protein is a hallmark of chronic myeloid leukemia.
Kinase dysfunction extends well beyond cancer. The JAK family of kinases transduces signals from cytokines, the chemical messengers of the immune system. When JAK signaling goes haywire, the immune system can turn on the body’s own tissues. Overactive JAK-STAT signaling has been linked to rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Kinase Inhibitors as Drugs
The realization that specific faulty kinases drive specific diseases opened the door to a major class of modern medicines: kinase inhibitors. The basic idea is to design a small molecule that slips into the kinase’s ATP-binding pocket and blocks it, preventing the enzyme from transferring phosphate groups. Since the ATP pocket is the engine room shared by all kinases, the design challenge is making an inhibitor selective enough to shut down the disease-causing kinase without crippling the hundreds of others the body depends on.
Researchers classify these inhibitors by how they interact with the kinase. Type I inhibitors bind the kinase in its active shape, sitting right where ATP normally goes. Type II inhibitors catch the kinase in an inactive shape, exploiting an extra pocket that only opens when the activation loop flips outward. This extra pocket gives drug designers more room to build in selectivity, because the inactive-state pocket varies more from kinase to kinase than the ATP site does.
Newer strategies push beyond the ATP pocket altogether. Allosteric inhibitors bind somewhere else on the kinase and lock it into a shape that can’t function. Covalent inhibitors form a permanent chemical bond with the kinase, which can produce longer-lasting effects and may help overcome drug resistance, though the irreversibility raises its own safety questions.
The poster child for kinase-targeted therapy is imatinib, designed to block BCR-ABL. Before imatinib, chronic myeloid leukemia was a grim diagnosis. With it, most patients achieve long-term remission. Dozens of other kinase inhibitors have followed, targeting kinases involved in lung cancer, breast cancer, kidney cancer, and melanoma, among others.
Antibody-based therapies take a different angle. Rather than sneaking a small molecule into the ATP pocket, monoclonal antibodies bind to the outside of receptor tyrosine kinases on the cell surface, blocking the signals that would normally activate them. The growth factor receptors EGFR and HER2 were the first to be targeted this way, and several antibodies against them are now standard treatments for certain breast and colorectal cancers. Because antibodies are large and highly specific, they tend to have a different side-effect profile than small-molecule inhibitors, though they come with their own limitations, including the need for intravenous delivery and high manufacturing costs.
Metabolic Kinases With Double Lives
For a long time, the kinase world seemed neatly divided: protein kinases handled signaling, and metabolic kinases handled energy chemistry. That boundary has blurred. Several enzymes traditionally classified as metabolic kinases, whose day jobs involve processing sugars or nucleotides, turn out to moonlight as protein kinases when conditions call for it.
Pyruvate kinase M2, for instance, is a glycolytic enzyme that normally processes sugar intermediates. But in cancer cells it can also phosphorylate proteins involved in gene expression and cell proliferation. Hexokinase and phosphoglycerate kinase 1 have been caught doing similar double duty. These moonlighting activities connect the cell’s metabolic state directly to its growth and survival decisions, which helps explain why cancer cells, with their famously warped metabolism, are so adept at rewiring signaling networks.
Pseudokinases and Why They Still Matter
About 60 members of the human kinase superfamily look like kinases on the outside but are missing the amino acids typically needed to transfer a phosphate group. These “pseudokinases” were once dismissed as evolutionary leftovers, molecular fossils that had lost their function. That assumption turned out to be wrong. Pseudokinases are conserved across bacteria, archaea, and eukaryotes, a strong hint that evolution has been keeping them around for a reason.
Many pseudokinases work as scaffolds or allosteric regulators. Instead of phosphorylating targets themselves, they bind to active kinases and change how those kinases behave, either boosting or dampening their activity. Some pseudokinases help assemble signaling complexes, bringing the right players together at the right time. A few have even been found to retain weak catalytic activity under specific conditions, blurring the line between “real” and “pseudo” further. Because pseudokinases are linked to cancer and other diseases, drug developers are beginning to explore them as targets, a tricky prospect since traditional kinase inhibitors are designed for an active ATP-binding pocket that pseudokinases lack.
How Researchers Study Kinases Today
Given that there are hundreds of kinases and potentially thousands of targets, figuring out which kinase phosphorylates which protein in which tissue at which moment is a massive puzzle. Classical genetics, where you knock out a gene and see what goes wrong, can only take you so far because kinases often compensate for each other.
One powerful modern approach is chemical genetics. Researchers engineer a kinase so that it accepts a slightly modified version of ATP that no other kinase in the cell can use. When they feed the cell this modified ATP, only the engineered kinase can use it to phosphorylate targets, and those targets get tagged with a chemical label that mass spectrometry can pick up. This lets scientists build a direct map of which proteins a specific kinase touches.
Phosphoproteomics, the large-scale cataloging of every phosphorylation event in a cell, has grown rapidly alongside improvements in mass spectrometry. A single experiment can now detect tens of thousands of phosphorylation sites across the proteome. Combined with time-course data and selective kinase inhibitors, this approach is painting an increasingly detailed picture of how kinase networks rewire themselves in disease, during development, and in response to drugs.
Subcellular mapping adds another layer. The kinome-mapping project that tagged and tracked hundreds of human kinases inside living cells revealed that many kinases are not evenly distributed but concentrated in specific compartments. Some shuttle between the cytoplasm and the nucleus; others are locked to membranes or organelles. These location patterns help explain why two kinases with similar biochemical activity in a test tube can have completely different biological effects in a living cell.
A Brief History of the Discovery
The story of kinases as we understand them today traces back to the mid-1950s and a puzzle about how hormones regulate the breakdown of glycogen, the stored form of sugar in muscle. Researchers studying the enzyme glycogen phosphorylase expected to find that a small molecule like AMP was the hormonal messenger. Instead, they discovered that the enzyme was being switched on by the attachment of a phosphate group, a reaction driven by calcium, ATP, and a then-unknown enzyme they named phosphorylase kinase. The reverse reaction, stripping the phosphate back off, was carried out by a phosphatase. This was the first demonstration that proteins could be turned on and off by phosphorylation, a finding that eventually earned a Nobel Prize and launched a field that now encompasses hundreds of drug targets, thousands of signaling pathways, and one of the most active areas of biomedical research.